AGIX-4207: Phase II

AGIX started a double-blind placebo-controlled U.S. Phase II study of AGIX-4207 combined with Remicade infliximab from Johnson & Johnson (JNJ, New Brunswick, N.J.) in 24 patients with RA. ...